Tirzepatide (brand names Mounjaro and Zepbound): A dual-action medication that activates both GLP-1 and GIP receptors, tirzepatide has demonstrated even more impressive weight loss outcomes, with studies showing average weight loss of 15.0% to 20.9% of body weight
OEM, , , ,
Journal of Inherited Metabolic Disease , 27(6):783-6 Locigno, R., Pincemail, J., Henno, A., Treusch, G
Position the spray nozzle in front of your mouth and spray 3 times under the tongue
In the FIGHT trial on patients hospitalized for HFrEF, Liraglutide did not show benefit on time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels from baseline to 180 days [51]